ReviewFrontiers in immunology2013
CD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive Vaccines.
Review in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 38 citations in OpenAlex.
- Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon.PLoS neglected tropical diseases · 2021Trial
- An ESAT-6-convergent prime-boost vaccination combining recombinant BCG expressing Mycobacterium marinum ESX-1 and ESAT-6/GLA-SE improves TB protection.NPJ vaccines · 2026Article
- Single-cell RNA sequencing reveals that kimchi dietary intervention modulates human antigen-presenting and CD4⁺ T cells.NPJ science of food · 2025Article
- Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine.iScience · 2025Article
- Evaluation of an interferon-gamma release assay for early detection of lumpy skin disease virus infection and vaccination in cattle.Microbiology spectrum · 2025Article
- Immune responses following neonatal vaccination with conserved F4 fragment of VtaA proteins from virulentVaccine: X · 2023Article
- Article
- Toward a general model of CD4Immunity · 2023Review
- Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.Frontiers in immunology · 2023Article
- Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question.Pharmaceutics · 2022Review
- Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change.Vaccines · 2022Review
- A multi-approach and multi-scale platform to model CD4+ T cells responding to infections.PLoS computational biology · 2021Article
- Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?Vaccines · 2021Article
- What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.Journal of Korean medical science · 2021Review
- Article
- Review
- Computational Analysis of Multiparametric Flow Cytometric Data to Dissect B Cell Subsets in Vaccine Studies.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020Article
- Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins ofFrontiers in immunology · 2019Article
- Optimized Protocol for the Detection of Multifunctional Epitope-Specific CD4Frontiers in immunology · 2019Article
- Role of the Microbiota in the Modulation of Vaccine Immune Responses.Frontiers in microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell priming is a critical event in the initiation of the immune response to vaccination since it deeply influences both the magnitude and the quality of the immune response induced. CD4(+) T cell priming, required for the induction of high-affinity antibodies and immune memory, represents a key target for improving and modulating vaccine immunogenicity. A major challenge in the study of in vivo T cell priming is due to the low frequency of antigen-specific T cells. This review discusses the current knowledge on antigen-specific CD4(+) T cell priming in the context of vaccination, as well as the most advanced tools for the characterization of the in vivo T cell priming and the opportunities offered by the application of systems biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.